SRI Innovation Partner

Center for Innovation Leadership

Ted is a biotech executive with 22 years experience evaluating translational development projects and leading multidisciplinary preclinical teams in cancer, neurology, and autoimmunity therapeutics. Currently an independent consultant, he is primarily responsible for running a unique collaboration between a foundation (Fast Forward LLC, the translational arm of the National Multiple Sclerosis Society) and a pharmaceutical company (EMD Serono) to identify, fund, and deliver novel therapeutic candidates from biotech and academic researchers. His pperational experience ranges from forming and supervising biotech R&D departments, to leading multidisciplinary teams to an IND submission, to managing academic collaborations (e.g. Oxford, UCSF) and a novel academic translational consortium (PharmaSTART- SRI, Stanford, UCSF, UCSD, UCB).

Ted has broad experience in reviewing, writing, and executing preclinical development plans for biotech companies, NIH, and foundations, with particularexpertise in neurology, immunology, and cancer. He has experience drafting and monitoring budgets, and delivering projects within timeline and budget parameters. He was trained in cellular immunology (Johns Hopkins University,Stanford University), with extensive experience in development and licensing of small molecules and biologics through roles as Director of Product Discovery, Sr. Director of Applied Research, and Sr. Director of Business Development.

Ted spent several years at SRI International where he ran the PharmaStart consortium, a novel academic preclinical program drafting development plans highlights include drafting a preclinical and clinical antibody plan for the NIH that let to over $100 M in contracts for SRI and its partner, redirecting a project to a new application and a $3.3M CounterACT development grant, licensing of several projects to biotechs, drafting a full development plan for a start-up funded by the Cystic Fibrosis Foundation and later became a senior director responsible for business development leadership including in- and out licensing of drugs for multiple sclerosis and breast cancer as well as incubation of a start-up company at SRI in return for equity.

Ted has hosted and chaired a number of conferences on preclinical development and biotech investing, and has that rare understanding of science as well as business.